X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (121) 121
index medicus (108) 108
humans (97) 97
melanoma (67) 67
female (65) 65
male (59) 59
middle aged (59) 59
cancer (57) 57
aged (53) 53
adult (48) 48
immunotherapy (48) 48
metastatic melanoma (39) 39
melanoma - drug therapy (38) 38
ipilimumab (33) 33
care and treatment (32) 32
aged, 80 and over (30) 30
antineoplastic agents - therapeutic use (28) 28
article (28) 28
treatment outcome (28) 28
melanoma - pathology (27) 27
chemistry (25) 25
metallurgy (25) 25
mutation (25) 25
nivolumab (25) 25
metastasis (24) 24
disease-free survival (23) 23
research (23) 23
immunology (20) 20
chemotherapy (19) 19
melanoma - genetics (19) 19
proto-oncogene proteins b-raf - genetics (19) 19
skin neoplasms - drug therapy (19) 19
survival (19) 19
vemurafenib (19) 19
antineoplastic agents - adverse effects (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (18) 18
abridged index medicus (17) 17
animals (17) 17
skin neoplasms - pathology (17) 17
tumors (17) 17
clinical trials (16) 16
dosage and administration (16) 16
neoplasm staging (16) 16
drug therapy (15) 15
melanoma - therapy (15) 15
sorafenib (15) 15
antimitotic agents (14) 14
antineoplastic agents (14) 14
cancer therapies (14) 14
medicine, research & experimental (14) 14
neoplasm metastasis (14) 14
pembrolizumab (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
carcinoma, renal cell - drug therapy (13) 13
dose-response relationship, drug (13) 13
indoles - adverse effects (13) 13
neoplasms - drug therapy (13) 13
patients (13) 13
anti-pd-1 (12) 12
antibodies, monoclonal - therapeutic use (12) 12
biomarkers (12) 12
health aspects (12) 12
indoles - therapeutic use (12) 12
kidney neoplasms - drug therapy (12) 12
open-label (12) 12
proto-oncogene proteins b-raf - antagonists & inhibitors (12) 12
targeted therapy (12) 12
glass (11) 11
mineral or slag wool (11) 11
performing operations (11) 11
therapy (11) 11
transporting (11) 11
antibodies, monoclonal - adverse effects (10) 10
blasting (10) 10
cell lung-cancer (10) 10
heating (10) 10
hematology, oncology and palliative medicine (10) 10
kaplan-meier estimate (10) 10
kinases (10) 10
lighting (10) 10
mechanical engineering (10) 10
medicine, general & internal (10) 10
meeting report (10) 10
safety (10) 10
usage (10) 10
weapons (10) 10
young adult (10) 10
braf (9) 9
braf inhibitor (9) 9
chemical composition of glasses, glazes, or vitreousenamels (9) 9
combination (9) 9
furnaces (9) 9
furnaces, kilns, ovens, or retorts in general (9) 9
indoles - administration & dosage (9) 9
joining glass to glass or other materials (9) 9
kilns (9) 9
kinase (9) 9
maximum tolerated dose (9) 9
medical research (9) 9
melanoma - immunology (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1749 - 1755
Journal Article
Journal of Translational Medicine, ISSN 1479-5876, 01/2015, Volume 13, Issue Suppl 1, pp. 1 - 2
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10032, pp. 2008 - 2016
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 11, pp. 1087 - 1095
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 378 - 388
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2010, Volume 363, Issue 9, pp. 809 - 819
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 18, pp. 1694 - 1703
The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in patients with metastatic melanoma produced a significantly higher response... 
CELL LUNG-CANCER | METASTATIC MELANOMA | MEDICINE, GENERAL & INTERNAL | EFFICACY | PATHWAY | SAFETY | KINASE | RESISTANCE | DOSE-ESCALATION TRIAL | RAF INHIBITORS | IMPROVED SURVIVAL | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Imidazoles - pharmacokinetics | Fever - chemically induced | Drug Therapy, Combination - adverse effects | Melanoma - genetics | Adult | Female | Imidazoles - therapeutic use | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | MAP Kinase Signaling System - drug effects | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Aged | Pyridones - therapeutic use | Mutation | Pyridones - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Melanoma | Product/Service Evaluations | Research | Antineoplastic agents | Antimitotic agents | Gene mutations | Causes of | Genetic aspects | Dosage and administration | Drug therapy, Combination | Drug therapy | Cell survival | Protein kinase | Skin diseases | MAP kinase | Kinases | Patients | Drug dosages | Fever | Metastases | Index Medicus | Abridged Index Medicus
Journal Article